MedTrace Logo

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2017-02-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.

Conditions

  • Irritable Bowel Syndrome With Diarrhea (IBS-D)

Interventions

DRUG

DNK333

DNK333 25mg b.i.d. given orally for 4 weeks

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals Corp. · NPC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394173 on ClinicalTrials.gov